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Abstract
A better understanding of changes in HIV-1 population genetics with combination antiretroviral therapy (cART) is critical for
designing eradication strategies. We therefore analyzed HIV-1 genetic variation and divergence in patients’ plasma before
cART, during suppression on cART, and after viral rebound. Single-genome sequences of plasma HIV-1 RNA were obtained
from HIV-1 infected patients prior to cART (N = 14), during suppression on cART (N = 14) and/or after viral rebound following
interruption of cART (N = 5). Intra-patient population diversity was measured by average pairwise difference (APD).
Population structure was assessed by phylogenetic analyses and a test for panmixia. Measurements of intra-population
diversity revealed no significant loss of overall genetic variation in patients treated for up to 15 years with cART. A test for
panmixia, however, showed significant changes in population structure in 2/10 patients after short-term cART (,1 year) and
in 7/10 patients after long-term cART (1–15 years). The changes consisted of diverse sets of viral variants prior to cART
shifting to populations containing one or more genetically uniform subpopulations during cART. Despite these significant
changes in population structure, rebound virus after long-term cART had little divergence from pretherapy virus, implicating
long-lived cells infected before cART as the source for rebound virus. The appearance of genetically uniform virus
populations and the lack of divergence after prolonged cART and cART interruption provide strong evidence that HIV-1
persists in long-lived cells infected before cART was initiated, that some of these infected cells may be capable of
proliferation, and that on-going cycles of viral replication are not evident.
Citation: Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, et al. (2014) Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral
Therapy. PLoS Pathog 10(3): e1004010. doi:10.1371/journal.ppat.1004010
Editor: Robert F. Siliciano, John Hopkins University, United States of America
Received May 31, 2013; Accepted February 3, 2014; Published March 20, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Funding for this research was provided with Federal funds from the National Cancer Institute, NIH. JMC was a Research Professor of the American
Cancer Society, with support from the FM Kirby Foundation. Supported in part (JWM) by funding from the National Cancer Institute (SAIC contract 25XS119). The
content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names,
commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: John Mellors is a consultant for Gilead Sciences and owns share options in RFS Pharmaceuticals. This does not alter our adherence to all
PLoS Pathogens policies on sharing data and materials.
* E-mail: kearneym@ncifcrf.gov
Introduction
The HIV-1 lifecycle includes rapid and error prone nucleic acid
replication that results in large and genetically diverse virus
populations in vivo. The consequences of broad HIV-1 genetic
diversity include the presence of viral variants containing
mutations that escape immune responses or confer resistance to
individual antiretroviral agents. The use of antiretroviral agents in
combination results in potent suppression of HIV-1 replication
and reverses immune deficiency, at least in part. Despite the ability
of cART to inhibit HIV-1 replication, treatment does not
eradicate infection and plasma viremia persists at low levels in
the majority of patients [1,2]. If cART is discontinued, viremia
rapidly rebounds to pre-therapy levels [3,4]. Determining the
sources and mechanisms for viral persistence during cART and
rebound after interruption is essential for designing strategies to
eradicate infection.
The dynamics of HIV-1 decay after initiating cART can be
divided into four phases [1,2,5]. The first phase, reflecting rapid
clearance of ca 90% of productively infected cells with half-life of
1–2 days, is followed by a more gradual clearance of infected cells
with a half-life of 2–3 weeks. A study by Palmer, et al. described a
third phase consisting of long-lived, perhaps latently-infected, cells
with a half-life of 6–44 months as well as a fourth phase having a
slope not significantly different from zero [1]. The plateau in the
fourth phase suggests that long-term cART fully inhibits HIV-1
replication and that the source of persistent viremia is either long-
lived virus-expressing cells or activation of virus expression from
latently-infected cells. In this regard, studies by Dinoso et al.,
McMahon et al., and Gandhi et al. showed no decrease in the level
of persistent viremia in patients on long term suppressive therapy
before, during, or after intensification with an additional
antiretroviral suggesting the absence of ongoing new rounds of
replication during suppressive cART [6,7,8]. Bailey et al.
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investigated plasma viral sequences after long-term cART and
found that HIV-1 populations often contain sets of identical
sequences, referred to as ‘‘predominant plasma clones,’’ suggesting
that viral subpopulations are lost over the course of treatment [9].
Wagner, et al. found an increasing frequency of identical sequences
in blood cells during cART suggesting proliferation of infected
cells [10], and Joos, et al. showed that homogeneous populations
rebound after cART interruption [11]. These findings suggest that
a reservoir of long lived infected cells, perhaps capable of
expansion, may be responsible for persistent viremia and its
rebound following interruption of cART.
In contrast to these findings, other studies have indicated that
low-level virus replication may occur in specific anatomical
compartments despite suppression of plasma HIV-1 RNA by
cART [12,13,14,15,16,17,18,19,20]. For example, in 2008, Chun,
et al. suggested that phylogenetic clustering of sequences obtained
from different cellular compartments after long-term cART
demonstrated cross-infection between reservoirs, consistent with
full cycles of replication as a source of persistent viremia [13].
Although such phylogenetic clustering may be indicative of on-
going replication, it may also result from compartmental mixing of
infected cells before or subsequent to initiating therapy. Demon-
strating the emergence of new viral variants during cART without
corresponding increases in total HIV-1 RNA would provide clear
evidence of virus replication. Previous studies that demonstrated
genetic change during therapy were in the context of drug
resistance, rebound viremia, or stimulation following vaccination,
each occurring in subsets of study patients in conjunction with
increases in plasma HIV-1 RNA levels, likely reflecting ineffective
therapy [12,14,21,22]. Several studies using integrase inhibitors to
intensify cART have detected transient increases in 2-LTR circles
in peripheral blood lymphocytes, especially in individuals under-
going protease inhibitor-based cART suggesting that some cells
may be newly infected during treatment [23] [24]. However,
changes in 2LTR circles were not associated with decreases in viral
RNA levels and genetic analyses did not show divergence during
the intensification period [25]. Notably, all of these clinical studies
have been conducted with patients already undergoing cART for
prolonged periods. No studies have investigated HIV-1 popula-
tions prior to and following initiation of cART. Comparing pre-
and post-therapy populations can shed new light on HIV-1
reservoirs, the sources of persistent viremia, and changes in HIV-1
populations at each phase of viral decay after introducing cART.
To investigate further the effect of cART on virus replication,
we examined HIV-1 populations in patients prior to cART, during
each phase of viral decay including long-term cART (fourth
phase), and during viral rebound after interruption of cART. By
investigating the genetics of HIV-1 in all phases of viral decay and
comparing on-therapy populations to pre-therapy virus we were
able to directly assess HIV-1 replication and molecular evolution
during long-term suppressive cART. We found that both short
and long lived cellular compartments were seeded with the same
diverse virus populations and that new viral populations rarely
emerged after up to 15 years of cART.
Materials and Methods
Study participants
Participants were enrolled in prospective studies aimed at
determining the role of antiretroviral therapy on HIV-1 infection
(protocols 97-I-0082, 08-I-0221) or on HIV-1 population genetics
in infected individuals (00-I-0110) conducted at the NIH Clinical
Center in Bethesda MD [26] [27]. All participants were $18 years
of age at study entry, with chronic HIV-1 infection (Fiebig Stage
VI) and reported no prior antiretroviral therapy (Table 1). Study
participants were enrolled from 1997–2002; Patients 2–4 and 6–13
initiated therapy with 2 NRTIs + nevirapine + indinavir as part of
a study of HIV-1 decay kinetics [26] and Patients 1, 5, and 14
initiated therapy with 2 NRTIs + efavirenz as part of a study of
HIV-1 population genetics [27] (Table 1). Frequent plasma
samples were obtained prior to and following introduction of
cART (Supplemental Table S1). Patients are described in Table 1
and samples analyzed in Supplemental Table S1. Patients were
categorized into three partially overlapping groups according to
their sample collection and treatment history (Table S1). Blood
samples were collected prior to initiating cART in all patients
(N= 14). In 10/14 patients (group 1) frequent samples were
collected during short-term treatment (up to one year on cART).
In 5 patients (group 2), samples were collected after long-term
therapy (average 9 yrs on cART), and in 5 patients (group 3),
samples were collected after a patient-initiated treatment inter-
ruption as well as after re-suppression in 3/5 (Table S1). Results
from the sequence analysis from all groups were compared to data
obtained using the same methods from a cohort of elite controllers
(data previously published) [28]. The elite controllers served as
untreated controls since they have similar levels of viremia (mean
0.8 copies/ml) without cART.
Ethics statement
All participants in this study were enrolled in clinical protocols
(00-I-0110, 97-I-0082, 08-I-0221) approved by the NIAID
Institutional Review Board (FWA00005897) administered at the
NIH Clinical Center in Bethesda, Maryland. Individuals under-
went an informed consent process and provided written consent
for participation.
HIV-1 genetic analyses of plasma samples
HIV-1 RNA levels were determined using bDNA Versant
version 3.0 (Bayer, Inc) as previously described [29]. Single-
genome sequencing (SGS) of a portion of HIV-1 gag-pro-pol
amplified from plasma HIV-1 RNA was performed as previously
described [30,31,32]. Sequences were aligned using ClustalW.
Population genetic diversity and divergence were calculated as
average pairwise difference (APD) using MEGA5 [33] (http://
www.megasoftware.net) and an in-house program [32]. Shifts in
Author Summary
Anti-HIV compounds are highly effective for preventing
the onset of AIDS but they do not cure infected
individuals. Very low levels of virus remain detectable in
the blood of most patients despite antiviral treatment and
levels surge if treatment is stopped. It is crucial to
understand why current treatments are not equipped to
cure HIV infection so that new therapies addressing these
shortcomings can be developed. By characterizing genetic
sequences of HIV in patients before and during antiviral
treatment, we found that the low levels of virus detected
in the blood of treated patients did not result from newly
infected cells but originated from cells, or the daughters of
cells, that were already infected when treatment was
initiated. This finding demonstrates that HIV present in
blood after prolonged antiviral treatment is derived from
cells infected prior to treatment which likely expanded
over time through cell division. Such long lived, infected
cells are likely the critical target for developing strategies
to cure HIV infection.
No HIV-1 Evolution during Antiretroviral Therapy
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population structure were calculated using a subdivision test for
panmixia with a significance cut off level of p,1023 as described
by the original report to account for the high number of
comparisons between sequences and nucleotide sites [34,35]
[27]. The probability of 1023 for assigning a significant change
in intra-patient HIV populations was derived statistically taking
into consideration that every nucleotide position is compared in
every two possible sets of sequences. This approach results in more
than 1012 comparisons between populations of only 10 sequences.
The test was derived from a geographic population structure test
proposed by Hudson et al. [36]. It compares the APD in single-
genome sequences obtained from samples taken at different times
(or places) to distances calculated from imaginary populations
containing the same sequences randomly reassigned to two groups.
Random mixing of the populations to be compared, reassignment,
and distance comparisons are performed 10,000 times, generating
a p-value for the probability that the randomized populations’
structures are the same between sets of sequences. Neighbor-
joining phylogenetic analyses were performed using MEGA5 [33].
Trees were rooted on the subtype B consensus sequence (http://
www.HIV-1.lanl.gov). Tests for molecular evolution were done
with BEAST [37] (http://beast.bio.ed.ac.uk) using the HYK+G
model with a relaxed clock, uncorrelated log normal and constant
size, followed by estimating the root to tip distances with
TreeStat1.2 (www.tree.bio.ed.ac.uk/software/treestat). Linear re-
gression was used to determine the slopes for the root-to-tip
analyses.
To investigate if genetic bottlenecks occurred after initiating
cART, we evaluated changes in the number of heterozygous sites
over time [38]. A genetic bottleneck was present if the number of
heterozygous sites in equal numbers of sequences in post-therapy
samples were in excess (chi-square probability,0.05) compared to
those in pre-therapy. We also investigated if CTL escape
mutations were enriched or depleted during cART by calculating
the allele frequencies at each amino acid position in pre-therapy
and post-therapy data in patients in group 1 and 2 with 7 or more
sequences at distal time points (N=8). Positions with amino acids
undergoing significant change in frequency after cART (Fisher
exact test 0.05) were identified and mapped onto predicted CTL
epitope maps [39]. Changes within the 9 amino acid peptide or in
+1 and -1 amino acids flanking the peptide were considered to be
part of the CTL epitope. The predicted binding affinities of the
pre- and post-therapy peptides were compared to determine if
amino acid changes occurring after initiating cART resulted in
decreased binding affinity; $10 fold decreases in affinity were
considered escape; $10 fold increases were considered return to
wild-type allele.
Results
Effect of cART on plasma HIV-1 diversity
To investigate the effect of cART on plasma HIV-1 diversity,
we assessed HIV-1 genetics by single-genome sequencing of
plasma HIV-1 RNA in individuals undergoing cART. Plasma
samples were obtained prior to and following introduction of
cART; and, for some patients, after planned patient-initiated
treatment interruptions. Single-genome sequences were obtained
at time points throughout the study period, and population
genetics parameters were measured. Genetic diversity was
measured by APD of virus populations in patients’ plasma prior
to treatment, during each phase of viral decay, and during viral
rebound (Figures 1, 2). Group 1 patients were sampled during the
first and second phases of HIV-1 decay on cART (up to 200 days)
to investigate the effect of declining viremia on virus diversity
(Figure 1a, 2a). Group 2 patients were sampled on long term
cART (c. 4–12 years) without treatment interruption during the
third and/or fourth phases of viral decay (Figure 1b, 2b). Group 3
patients with long-term suppression of HIV-1 underwent brief
planned treatment interruptions and were sampled before and
after treatment initiation and after virus rebound (Figure 1c, 2c).
Most patients (13 of 14) showed no significant difference in APD
of HIV-1 populations during any phase of viral decay, after long-
term therapy, or after viral rebound, compared to pre-therapy
virus populations (Figure 1, 2). This finding shows, in most cases,
that HIV-1 plasma diversity is not associated with the level of
viremia (Figure 2), with the duration of cART, or with viral
rebound after stopping cART. Figure 1 shows the diversity of
plasma HIV-1 populations in each patient before and during or
after interruption of cART (the value above the bar in Figure 1
shows the number of years the sample was collected after initiating
cART). Of 14 patients, only one (PID 8) showed a significant
reduction in viral diversity after treatment with cART (Figure 1b,
2b). The mean virus diversity across patients in each group and as
a whole did not change after initiation of cART or during cART
(Figure 1d), indicating that plasma virus diversity is sustained
during each phase of viral decay despite the large decreases in the
replicating population size. This result suggests that the cellular
reservoir of persistent viremia in most patients is seeded with the
same highly diverse replicating population of virus that exists prior
to therapy. This observation is in contrast to elite controllers who
have significantly lower levels of diversity than noncontrollers
(p = 0.005) [28] correlating with their lower levels of viremia. The
contrasting results suggest that the infected cell population in
patients treated with cART is large while the reservoir of infected
cells in elite controllers is likely to be significantly smaller.
Effect of cART on number of alleles
Although HIV-1 populations revealed no significant change in
APD with cART, genetic bottlenecks may occur in large, diverse
populations without producing a detectable change in the overall
diversity. During a bottleneck, low frequency alleles, which do not
contribute substantially to overall diversity or to phylogenetic
signal, are lost [38]. As a result, the total number of alleles is
decreased while the diversity is maintained. Because bottlenecks
will have substantial effects on the occurrence of low frequency
alleles, we specifically investigated the total number of alleles prior
to and following introduction of cART (Table 2) in patients with
sampling during viral RNA decay on therapy (N=9). We found a
significant decrease in the numbers of alleles in only a single
patient (PID 1), suggesting that a genetic bottleneck occurred in
this patient alone. In two patients (PID 2 and 7), a modest but
detectable increase in alleles occurred suggesting genetic shifts but
not population contraction. The remaining patients had no
changes in the numbers of alleles (Table 2), indicating that, for
the majority of individuals, no genetic bottleneck accompanies the
profound decrease in HIV RNA after initiation of cART.
To specifically investigate whether prolonged HIV-1 suppression
resulted in changes in amino acid sequences, we investigated
nonsynonymous changes alone in patients from groups 1 and 2 for
which there were more than 7 sequences at time points with ,50
copies/ml (N=8) (Table S2). We found that amino acid frequencies
were remarkably stable during cART. In fact, virus populations in
4/8 patients had no significant change at any of the PR or RT loci.
As all enrolled patients underwent HLA testing, we were able to
investigate, using in silico techniques, the predicted positions of all
the CTL epitopes in the HIV-1 sequence as well as the estimated
binding affinity of all the HIV-1 peptides at each epitope site [39].
As shown in Table S2, there was no consistent trend to enrich or
No HIV-1 Evolution during Antiretroviral Therapy
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deplete CTL escape mutations after prolonged cART suppression,
including in those patients who underwent a significant population
shift (e.g., PID 1). Taken together, these data suggest that the
population of virus-producing cells present after prolonged
suppression is not shaped in a substantial way by new CTL
selection following introduction of cART. This finding is in stark
contrast to the strong selection at CTL epitopes in elite controllers
ranging from 11–66% of epitopes carrying escape mutations [28].
Figure 1. Measurements of HIV-1 diversity calculated as APD before, during and/or after cART in all patients in (A) Group 1 - short-
term cART (B) Group 2 - long-term cART (C) Group 3 - cART with treatment interruptions and (D) the average of all groups. Duration
of treatment is shown in years in parentheses above the bar with the diversity measurement. Overall, HIV-1 plasma diversity did not change with
initiation of therapy.
doi:10.1371/journal.ppat.1004010.g001
No HIV-1 Evolution during Antiretroviral Therapy
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Effect of cART on HIV-1 population structure and
divergence
Divergence of HIV-1 populations during cART could result
either from on-going cycles of replication leading to the emergence
of new variants or as a consequence of shifts in the viral variants
present in the plasma during suppression, indicating a dynamic
reservoir. To investigate the possibility of population shift
(divergence) during cART, we used a test for panmixia to detect
changes in the population structure during therapy compared to
pretherapy virus. The panmixia test compares populations of
single-genome sequences obtained from longitudinal samples and
provides a p-value for the probability that the populations are the
same [34]. Probabilities of ,1023 were considered to indicate
significantly different populations, taking into account the large
numbers of comparisons. Figure 3 and Table 3 show the panmixia
results for single-genome sequences from group 1 (Figure 3a,
Table 3), group 2, (Figure 3b, Table 3), and group 3 (Figure 3c,
Table 3) compared to pretherapy sequences. Panmixia probabil-
ities of virus populations in samples collected from patients on
cART compared to pre-therapy populations did not achieve
significance (Figure 3a) in 8/10 patients from group 1. These
results indicate that there is typically no significant shift in the
plasma virus population during the first and second phases of
decay after initiating cART despite up to 10,000-fold declines in
levels of viremia. Two patients in group 1 (PID 6, 7), however, did
show a significant change in population structure after 173 and
193 days on therapy. Additional analyses describing the nature of
these changes are presented below. Three of 5 patients in group 2
(long-term cART) showed a significant change in population
structure during cART for 4–12 years with no treatment
interruptions, suggesting either that new variants emerged during
therapy or that the reservoir for persistent viremia is dynamic.
Figure 2. HIV-1 plasma RNA copy numbers and diversity as calculated by APD in longitudinal samples prior to and during cART in
selected patients on (A) short-term cART (Group 1) (B) long-term cART (Group 2) and (C) cART with treatment interruptions (Group
3). We found no relationship between HIV-1 RNA copy number and viral diversity in the plasma.
doi:10.1371/journal.ppat.1004010.g002
No HIV-1 Evolution during Antiretroviral Therapy
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Four of 5 patients in group 3 (long-term cART but with brief
treatment interruptions) showed a significant shift in population
structure using the panmixia test. The results from group 2 and 3
show that, although plasma HIV-1 populations do not typically
change in the early phases of viral decay, shifts in virus populations
(without a change in overall diversity) are readily detectable after
long-term therapy and in rebound viremia. They imply that either
a compartment allowing on-going cycles of replication exists
during cART or subsets of infected cells expressing virus particles
shift over the course of treatment (through proliferation and/or
death).
Effect of cART on HIV-1 phylogenetic structure
To further determine if the population shifts detected in the
plasma of some patients during and after long-term cART were
the result of on-going cycles of virus replication or were due to a
shift in the population of cells that express virus particles during
therapy, we performed phylogenetic analyses and tests for
molecular evolution. Such tests can detect with high sensitivity
the emergence of new viral variants indicative of full cycles of
replication during cART. We used neighbor-joining trees to first
evaluate the direct relationship of the sequences obtained prior to,
during, and after therapy and we subsequently used tests for
molecular evolution and calculations of root-to-tip distances to
detect the emergence of new virus populations during cART.
Figure 4a shows two examples of the population structure in
patients in group 1 who had no detectable shift in the virus
population using the test for panmixia or the divergence analysis.
Consistent with the panmixia results, the structure of sequences
obtained during viral decline (gray triangles) and early suppression
on cART (black triangles) showed no change from pre-therapy
virus (open circles). Figure 4b shows the neighbor-joining trees for
the two additional patients in group 1 (PID 6, 7) whose virus had a
detectable shift in the population during short-term treatment with
cART using the test for panmixia. It is evident from the trees that
the shift in population and significant panmixia resulted from
clusters of identical sequences that were revealed when levels of
viremia were ,50 copies/ml (circled black triangles). To confirm
that the identical sequences found in PID 6 and 7 resulted in the
population shift measured by the test for panmixia, we collapsed
the alignment to include only one of each identical sequence and
repeated the test. The collapsed alignments resulted in p values of
0.044 and 0.011, respectively, for panmixia (not significant),
rejecting the null hypothesis. The revealing of populations of
identical sequences during therapy suggests that either a single
infected cell is proliferating and releasing virus resulting in a
dominant variant appearing in the plasma or that a single variant
is expanding through full cycles of replication despite cART.
Additional analyses to investigate this question are presented later.
Phylogenetic trees of virus sequences from 6 patients on long-
term cART are shown in Figure 4c–d. Trees from representative
patients in group 2 (long-term suppression - Figure 4c) and group 3
(re-suppression after brief treatment interruption - Figure 4d) show
that the population shift detected by the test for panmixia in these
groups resulted from clusters of identical sequences in the plasma
(black triangles), and not from additional accumulation of
mutations. As noted above, patient 8 was the only one who also
showed a significant change in the diversity of the virus population
during therapy. The phylogenetic analysis shows that the loss of
diversity of the virus population in this patient also resulted from
over-representation of identical sequences in the plasma, possibly
masking the presence of other viral variants. The presence of
identical sequences after long-term cART suggests a proliferating
infected cell population as a major source of persistent viremia
during therapy. These data also suggest that the virus-producing
reservoir of HIV-1 infection may contract during prolonged
Table 2. Allele frequency during cART.
Patienta
Therapy
Period
Number of
Sequences
Total Number
of Alleles
Total Number of
Homozygous Sites Heterozygosity Chitest
1 Pre therapy 38 546 978 0.13
1 Post therapy 38 415 986 0.13 0.0004
2 Pre therapy 12 146 1010 0.10
2 Post therapy 12 197 987 0.12 0.01
4 Pre therapy 49 124 1021 0.08
4 Post therapy 49 105 1062 0.05 0.14
5 Pre therapy 99 1077 885 0.21
5 Post therapy 99 1109 836 0.25 0.18
6 Pre therapy 45 323 1010 0.10
6 Post therapy 45 283 1009 0.10 0.16
7 Pre therapy 23 87 1056 0.06
7 Post therapy 23 117 1037 0.08 0.03
9 Pre therapy 31 128 1036 0.08
9 Post therapy 31 109 1021 0.09 0.29
11 Pre therapy 22 248 1016 0.10
11 Post therapy 22 262 1011 0.10 0.55
14 Pre therapy 20 130 1035 0.08
14 Post therapy 20 129 1038 0.08 0.94
aAnalysis includes only patients who had sampling during viral RNA decay on cART.
doi:10.1371/journal.ppat.1004010.t002
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cART. In addition to the identical sequences, there were also some
unique sequences detected in patients in groups 2 and 3 after long-
term suppression. The presence of unique variants in the plasma
during long-term treatment in PID 1 (Figure 4c) may indicate that
on-going replication is another source of residual viremia during
therapy in this patient. However, unique variants present in PID
11 (Figure 4c) are more likely due to replication that occurred
during the brief treatment interruption in this patient.
Figure 3. Measurements of the probability of panmixia before and after cART in (A) Group 1 - short-term cART (B) Group 2 - long-
term cART (C) Group 3 - cART with treatment interruptions. We considered a panmixia p value of ,0.001 to be statistically significant
according to the original publication of the method (1). Significance reveals a shift in population over time on cART and was found primarily in
patients on long-term cART.
doi:10.1371/journal.ppat.1004010.g003
No HIV-1 Evolution during Antiretroviral Therapy
PLOS Pathogens | www.plospathogens.org 8 March 2014 | Volume 10 | Issue 3 | e1004010
The genetics of rebound viremia are shown in two patients
from group 3 (PID 2, 9) in Figure 5; and demonstrate that
rebounding virus is primarily due to populations of identical
sequences, as seen during cART, suggesting a stable, non-
evolving reservoir as a likely source of rebound viremia. The
presence of multiple populations of rebounding virus argues
against the identical sequences persisting during suppression
being the source of viral rebound since, in most patients, we
detected only a single population of identical variants during
suppression. Rebound viremia in these two patients also
includes unique variants, some of which may be recombinants
between the rebounding rakes of identical sequences and
accumulation of new mutations that occurred after interrupting
cART.
Neighbor-joining analyses allowed us to visualize the plasma
virus populations present during cART compared to those in
pretherapy, but cannot be used to determine if the variants
present during treatment are newly emergent resulting from full
cycles of replication or if they are merely the expression of
variants from cells infected prior to treatment. For this purpose,
we applied a test for molecular evolution using Bayesian analysis
as implemented in BEAST (http://beast.bio.ed.ac.uk) to deter-
mine if the plasma virus populations present during therapy were
newly emergent variants or were pre-existing. The molecular
evolution test was performed by measuring the distances from the
root of the tree (rooted on consensus B) to the tip of each branch
(Figure 6a–d). If the population structure results from the
emergence of new variants, then those sequences will be on
branches that are more distant from the root of the tree
than variants present in pre-therapy, resulting in positive
slopes in Figure 6 as shown in Table 3. The molecular
evolution test revealed slopes that were close to 0 (med-
ian = 16102564.561025 nt/day) with no significant differences
between groups (t-test between groups 1 and 2 had p
value = 0.72, between groups 2 and 3 p= 0.67, and between
groups 1 and 3 p= 0.74), showing that the variants present during
the second and third phases of decay and after prolonged therapy
were not more distant from the root of the tree than variants
present prior to initiating therapy. In a few cases the sequences
were actually slightly closer to the root (consensus B) resulting in a
negative slope. By contrast, the slopes in untreated elite
controllers with similar levels of viremia have significantly
positive slopes (median = 15 nt/day) (p = 0.009) when measured
over similar intervals [28]. These findings indicate that the viruses
with identical sequences that are revealed during cART are not
the result of full cycles of replication, but are likely being released
from a proliferating cell population that was infected prior to
therapy. Although all patients had root-to-tip slopes close to 0,
one had a slightly but significantly positive slope after long-term
treatment (PID 1, Figure 6a,b, Table 3) suggesting that there is a
subset of patients for whom treatment (for some period) is not
fully suppressive. The remaining 13/14 patients had slopes not
Table 3. Divergence from pretherapy virus.
PID Groupa Sample Description Probablility of Panmixia Root to Tip Sloped
1 1 26 days on cART 0.0134 0.2
2 1 41 days on cART 0.4505 20.03
3 1 80 days on cART 0.0609 20.0006
4 1 110 days on cART 0.4032 20.001
5 1 260 days on cART 0.1358 0.002
6 1 193 days on cART 0.0006* 0.0001
7 1 173 days on cART 0.0003* 20.0009
9 1 136 days on cART 0.258 20.0002
11 1 23 days on cART 0.4927 20.02
14 1 111 days on cART 0.0733 20.0007
1 2 1566 days on cART ,0.000001 0.02
4 2 3650 days on cART ,0.000001 0.00009
8 2 3437 days on cART ,0.000001b 0.00008
10 2 4380 days on cART 0.3311 0.00003
12 2 3215 days on cART 0.573c 20.002
2 3 Rebound viremia after 2624 days on cART ,0.000001 0.005
3 3 Rebound viremia after 2013 days on cART 0.0085 0.0009
9 3 Rebound viremia after 1497 days on cART ,0.000001 0.001
11 3 Rebound viremia after 3255 days on cART 0.00001 0.002
13 3 Rebound viremia after 755 days on cARY ,0.000001 0.002
aGroup definitions: Group 1 - Samples analyzed pre-cART and ,1 yr on cART. Group 2 - Pre-cART and after long-term suppression on cART (average 9 yrs on cART).
Group 3 - Pre-cART and after treatment interruption.
b4 Sequences only.
c3 Sequences only.
dnt/day multiplied by 1000.
Bold - significant p value.
doi:10.1371/journal.ppat.1004010.t003
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Figure 4. Neighbor-joining trees of single-genome plasma sequences from select samples from (A) Group 1 - short-term cART with
no significant divergence of virus population from pre-therapy virus (B) Group 1 - short-term cART with significant divergence of
virus during suppression on cART (C) Group 2 – long-term cART and (D) Group 3 – long-term cART, resuppression after a brief
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significantly different from zero consistent with complete
suppression of viral replication.
Discussion
The source(s) of persistent viremia during suppressive antiret-
roviral therapy remains uncertain, and there have been a number
of studies to investigate whether repeated full cycles of virus
replication occur during adherence to cART or if low-level
viremia present in the plasma of successfully treated patients is the
result of viral expression from long-lived cells infected prior to
treatment. Population genetics and phylogenetic approaches
represent powerful techniques to detect genetic change in
temporally spaced samples, but in the setting of relatively high
genetic diversity it is often difficult to determine whether observed
change represents molecular evolution from ongoing replication or
a shift in the population of reservoir cells producing virus. One
way to resolve this issue is to compare HIV-1 populations prior to
and following initiation of cART and to compare temporal
changes in viral populations in treated patients to untreated elite
controllers with similar levels of viremia and duration of control.
In this study, we investigated HIV-1 gag-pro-pol populations in
infected individuals before, during, and after cART by analyzing
the effect of cART on viral genetic diversity and population
structure and compared the results to similar data set from a
cohort of elite controllers [28]. We previously showed that viral
treatment interruption. Phylogenetic analyses reveal populations of identical plasma sequences after long-term cART suggesting virus release
from a long-lived proliferating cell population.
doi:10.1371/journal.ppat.1004010.g004
Figure 5. Neighbor-joining trees of single-genome plasma sequences from rebound viremia in patients in Group 3. Phylogenetic
analyses reveal populations of identical plasma sequences in rebound viremia after interrupting long-term cART.
doi:10.1371/journal.ppat.1004010.g005
No HIV-1 Evolution during Antiretroviral Therapy
PLOS Pathogens | www.plospathogens.org 11 March 2014 | Volume 10 | Issue 3 | e1004010
replication and molecular evolution occur in spontaneous HIV-1
elite controllers at levels that are not significantly different from
non-controllers [28]. This finding demonstrates that our analytical
methods are sensitive enough to detect the emergence of new viral
variants despite very low levels of viremia. In fact, with these
methods, we are able detect the emergence of new variants even if
evolutionary rates are only 10% of those measured in elite
controllers (15 nt changes/day). To address the question of
ongoing replication during cART, we applied the same analytical
approach used in the elite controller cohort [28] to HIV-1
populations in non-controllers on cART for evidence of molecular
evolution during treatment. In contrast to our findings in elite
controllers, we found clear evidence for virus molecular evolution
in only one patient on long-term cART (without treatment
interruptions) while we found no evidence for the appearance of
new variants in any of the other suppressed patients.
First, we investigated virus populations in samples collected
within the first 6 months of initiating cART and compared these
populations to the viral sequences obtained from pretherapy
samples. We found no change in the diversity, divergence, or
phylogenetic structure in populations obtained before and after 6
months of ART, and no evidence of any genetic bottleneck in 8/9
patients on study. These results indicate that both short- and long-
lived cellular compartments are seeded with the same viruses and
that these compartments are sufficiently large to support highly
diverse populations of HIV-1 genomes. The sustained diversity of
HIV-1 populations over months of suppressive therapy without a
genetic bottleneck or loss of low frequency alleles also implies that
pre-existing low-level drug resistance mutations are not likely to be
lost during antiretroviral therapy.
To investigate the genetics of persistent HIV-1 during long-term
cART, we also sequenced plasma virus populations during 4–15
years of suppressive therapy; and again, compared these popula-
tions to those obtained from pretherapy samples. In contrast to
earlier samples on cART, we found clusters of identical sequences
in plasma samples collected after long-term treatment. However,
using phylogenetic tests for molecular evolution (root-to-tip
distance analyses), we found no evidence for the appearance of
new variants during long-term cART and the clusters fit within the
phylogenies of virus populations present before therapy (with the
exception of one patient). The presence of identical sequences
during ART suggests that virus particles are being produced by an
HIV-1 infected clonal cell population, such as stem cell-like CD4+
memory T-cells or other proliferating cell types. These conclusions
are consistent with previous studies that indicate that persistent
plasma viremia during cART is derived from viral expression in
long-lived cells [9,11] [1] [6,7,8]. The specific cell populations
giving rise to plasma viremia during cART have not yet been
determined but one study nicely demonstrated significantly
different populations structures between residual viremia and
resting CD4+ cells in 11/13 patients [40] suggesting alternative
sources for persistent viremia.
Given that long term therapy reduces the average level of
viremia from about 30,000 to about 1–3 copies of RNA per ml on
average [1] and that a minority (up to about 1/3) of the sequences
in patients on long term therapy are clonal, we can estimate that
the cells that produce such virus represent about 1 in 100,000 of
Figure 6. Evolutionary distances of each single-genome
sequence from pre-cART and during and after cART compared
to the consensus subtype B HIV-1 sequence and plotted over
(A) short-term cART (B) long-term cART (C) long-term cART
with brief treatment interruptions and (D) rebound viremia.
Positive slopes indicate the emergence of new variants and on-going
replication during cART. Only one patient (PID 1) showed a positive
slope and evidence of molecular evolution during cART.
doi:10.1371/journal.ppat.1004010.g006
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the total virus-producing cell population in an untreated individ-
ual. Our findings also suggest that these cells are neither expanded
nor depleted during therapy as a result of CTL selection. Our
observations and those of others (14) that rebound viremia after
long-term cART contains homogeneous populations suggests that
rebound viremia results from the expansion of identical sequences
present during suppression or from a small number of founder
viruses (as seen in acute infection). Further experiments are
required to determine the relationship of virus populations that
persist during therapy to those that rebound after treatment
interruption.
The conclusion that cART effectively and completely halts
HIV-1 replication in those infected cells that are responsible for
viremia is consistent with prior studies by us and others showing
that low levels of viremia on therapy are independent of the
therapeutic regimen used and they cannot be further suppressed
by additional drugs [6,7,8]. Our conclusions are also consistent
with the initial observations of Persaud and coworkers who
demonstrated that drug resistant mutations do not emerge in
patients with suppressed viremia [41]. Several observations,
including transient increases in 2LTR circles in some cART
treated patients undergoing raltegravir intensification, and studies
measuring relative levels of HIV-1 RNA in specific compartments
[42] have suggested the presence of localized, limited HIV-1
replication. However, the relationship between the 2-LTR circles
and low level viremia has not been firmly established. It is likely
that a very small fraction of the virions released during suppressive
cART give rise to the 2 LTR circles and that these represent dead-
end events, not continuous replication, most likely related to the
use of a specific antiviral treatment regimen [42]. Our findings
here suggest that low level viremia persisting during cART results
primarily from expression of virus in expanding cell populations
infected prior to initiating therapy. Cure of HIV-1 infection will
require strategies that either eliminate the extremely rare cell
population that can chronically produce infectious virus or prevent
regrowth of virus from these reservoirs following cessation of
cART.
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